产品说明书
Topotecan HCl
 |
同义名 : | 盐酸拓扑替康 ;SKF 104864A hydrochloride;NSC 609669 hydrochloride;SKF 104864A;NSC 609669;Topotecan (hydrochloride);NSC 609699;SKFS 104864A;Nogitecan HCl;Topotecan HCl |
| CAS号 : | 119413-54-6 | |
| 货号 : | A122669 | |
| 分子式 : | C23H24ClN3O5 | |
| 纯度 : | 98% | |
| 分子量 : | 457.91 | |
| MDL号 : | MFCD00866235 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(229.3 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 30 mg/mL(65.52 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
PO 0.5% CMC-Na 33 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Topotecan Hydrochloride (SKF 104864A Hydrochloride) effectively inhibits the proliferation of human glioma cells and glioma stem cells (GSCs) in a dose- and time-dependent manner. An optimal administration concentration of 3 μM is selected based on IC50 values at 24 h. Topotecan Hydrochloride induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Additionally, it inhibits cell viability in a dose-dependent manner [1]. | ||
| 细胞研究 | |||||
|---|---|---|---|---|---|
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
| A427 human lung carcinoma | Proliferation assay | Antiproliferative activity measured against A427 human lung carcinoma, IC50=49 nM | 9876111 | ||
| COR-L23/P cell | Cytotoxic assay | Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line, IC50=13.2 nM | 11806724 | ||
| HeLa cells | Growth inhibition assay | Growth inhibition of HeLa cells after 4 days, GI50=30 nM | 17418582 | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00231855 | Ovarian Neoplasms ... 展开 >> Uterine Neoplasms 收起 << | Phase 2 | Completed | - | United States, New York ... 展开 >> Montefiore Medical Center Bronx, New York, United States, 10461 收起 << |
| NCT00466232 | Small Cell Carcinoma ... 展开 >> Lung Cancer 收起 << | Phase 1 | Completed | - | United States, Minnesota ... 展开 >> Park Nicollet Institute St. Louis Park, Minnesota, United States, 55416 收起 << |
| NCT00170625 | Ovarian Cancer | Phase 1 Phase 2 | Completed | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.92mL 2.18mL 1.09mL |
21.84mL 4.37mL 2.18mL |
| 参考文献 |
|---|